New combo aims to fight relapsed leukemia after transplant

NCT ID NCT05772273

Recruiting now Disease control Sponsor: The First Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a combination of a PD-1 inhibitor (camrelizumab), a chemotherapy drug (azacitidine), and donor immune cells (DLI) in 43 adults with acute myeloid leukemia that has returned after a stem cell transplant. The goal is to see if this approach can help patients achieve remission again. The trial is currently recruiting participants aged 18 to 60 with adequate organ function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Camrelizumab (PD-1 inhibitor), azacitidine, and donor lymphocyte infusions
What this could lead to: If successful, this combination could offer a new treatment option for patients whose AML returns after a stem cell transplant, potentially improving remission rates.
What could go wrong: This is a small, early-phase study with only 43 participants, so results may not apply widely. The combination also carries risks like graft-versus-host disease and immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

The First Affiliated Hospital of Soochow University
RECRUITING

Suzhou, Jiangsu, 215006, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.